Successful sequential antiangiogenic therapy for alveolar soft part sarcoma - a case report

被引：0
作者：
Schultheis, B. [1 ]
Kummer, G. [1 ]
Tannapfel, A. [2 ]
Strumberg, D. [1 ]
机构：
[1] Univ Bochum, Marienhosp Herne, Dept Hematol & Oncol, Herne, Germany
[2] Univ Bochum, Dept Pathol, Berufsgenossenschaftliches Univ Klinikum Bergmann, Herne, Germany
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | 2010年 / 48卷 / 07期
关键词：
alveolar soft part sarcoma; antiangiogenic therapy; quality of life; EXPRESSION; INHIBITOR;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：468 / 469
页数：2
相关论文
共 6 条
  • [1] Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma
    Azizi, Amedeo A.
    Haberler, Christine
    Czech, Thomas
    Gupper, Astrid
    Prayer, Daniela
    Breitschopf, Helene
    Acker, Till
    Slavc, Irene
    [J]. LANCET ONCOLOGY, 2006, 7 (06) : 521 - 523
  • [2] Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group
    Casanova, M
    Ferrari, A
    Bisogno, G
    Cecchetto, G
    Basso, E
    De Bernardi, B
    Indolfi, P
    Bellani, FF
    Carli, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (11) : 1445 - 1449
  • [3] Alveolar soft-part sarcoma responsive to intensive chemotherapy
    Nickerson, HJ
    Silberman, T
    Jacobsen, FS
    Krawisz, BR
    Maki, HS
    Arndt, CAS
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2004, 26 (04) : 233 - 235
  • [4] Alveolar soft-part sarcoma responding to interferon alpha-2b
    Roozendaal, KJ
    de Valk, B
    ten Velden, JJA
    van der Woude, HJ
    Kroon, BBR
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (02) : 243 - 245
  • [5] Gene expression profiling of alveolar soft-part sarcoma (ASPS)
    Stockwin, Luke H.
    Vistica, David T.
    Kenney, Susan
    Schrump, David S.
    Butcher, Donna O.
    Raffeld, Mark
    Shoemaker, Robert H.
    [J]. BMC CANCER, 2009, 9 : 22
  • [6] Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours
    Trarbach, T.
    Drevs, J.
    Strumberg, D.
    Gauler, T. C.
    Schneider, V.
    Eberhardt, W. E.
    Collins, B.
    Marotti, M.
    Swaisland, A. J.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
1